APRE logo

APREAprea Therapeutics Inc

$0.7414
$0.0339
(4.37%)
Today
Closed $0.7414
$0.0214
(2.89%)
After Hours
Updated: 07:07 PM EDT
Mkt Cap$9.18M
Vol108,950.00
News
all
press releases
Aprea Therapeutics (APRE) Upgraded to Buy: Here's What You Should Know
Aprea Therapeutics (APRE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks
News Placeholder
More News
News Placeholder
Aprea Therapeutics Stock Rises After Company Reports Second Unconfirmed Case Of Tumor Reduction In Trial
The company reported a second unconfirmed partial response in a patient with advanced endometrial cancer being treated at the 220 mg dose level.
Stocktwits
News Placeholder
Aprea Therapeutics Advanced Cancer Trial Shows Promising Results, Stock Soars
Aprea Therapeutics shares rise after promising Phase 1 trial results with APR-1051 in cancer treatment.read more...
Benzinga
News Placeholder
New Strong Sell Stocks for January 19th
APRE, NFE and CZR have been added to the Zacks Rank #5 (Strong Sell) List on January 19, 2026.
Zacks
News Placeholder
New Strong Sell Stocks for Jan. 14
APRE, CULP and PSKY have been added to the Zacks Rank #5 (Strong Sell) List on Jan.13, 2026.
Zacks
News Placeholder
Marc Duey Acquires 21,459 Shares of Aprea Therapeutics (NASDAQ:APRE) Stock
Aprea Therapeutics, Inc. (NASDAQ:APRE - Get Free Report) Director Marc Duey purchased 21,459 shares of the firm's stock in a transaction on Wednesday, December 10th. The shares were acquired at an...
MarketBeat
<
...
1
>